Jonathan Loree

GI Medical Oncologist at BC Cancer, Associate Professor at The University of British Columbia, Senior Investigator at the Canadian Cancer Trials Group (CCTG)

[Thor Halfdanarson @OncoThor]

This is an absolutely outstanding review on the management of patients with metastatic gastric cancer.

I may have posted about this review before but it is so good that it deserves another round of applause... Thanks @KlempnerSam @YJanjigianMD @amalsargsyan and all the other co-authors I could not find on X...

Sorry AI, I love you but you are just not there yet. True content experts writing a practical review still beat you easily.

This should be a required read for all who take care of patients with gastric cancer.

https://t.co/5eCIbBwK7G

[Jonathan Loree @jonathanloree]

@GillSharlene @CDNCancerTrials @JeanneTie Great to hear from @JeanneTie and look for new opportunities to work together with @GICancer. Also excited to plan the BATTMAN trials upcoming launch in Australia and New Zealand. Botensilimab plus balstilimab in #mcrc

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

#CCTG2026 @CDNCancerTrials 🇨🇦
A pleasure to host @JeanneTie to our CCTG Annual Meeting to advance our strong history of trials collaboration with @GICancer #formerlyAGITG 🇦🇺 🇳🇿
Special shout out to her #ILoveCanada earrings! ❤️

[OncoDaily GI @OncoDailyGI]

🌐 BATTMAN trial begins in MSS metastatic colorectal cancer

On April 1, 2026, Agenus announced that the first patient has been enrolled in the phase III BATTMAN trial.

BATTMAN is a global, randomized phase III study evaluating botensilimab + balstilimab vs best supportive care in patients with refractory, unresectable MSS metastatic colorectal cancer.

The trial is being conducted across international sites and represents a potential registrational study in this setting.

@Agenus_Bio @oncodaily @jonathanloree @garo_armen

📎https://t.co/beAJM9r3Zm

#OncoDaily #GIOncology #ColorectalCancer #Immunotherapy #ClinicalTrials

[Hagen Kennecke @HKennecke]

Sharing the final publication and schema! @NANETS1 Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors https://t.co/UDLJ8ZI75f

[Hagen Kennecke @HKennecke]

@OHSUKnight study showed standard dose (35mg/m2 bid) Trifluridine (Lonsurf) wk 1, 3 and 5 of #radiation for stage 2/3 #rectalcancer was safe with TNT. 56% of patients did Watch and Wait.
➡️New option for patients with 5-FU toxicity/contraindications❓

https://t.co/YriIxXipl6

[Hagen Kennecke @HKennecke]

Check out our new @NANETS Guidelines for Stage I-III Rectal NETs! Big updates in:
- staging with MRI & PET Dotatate
- advanced excision for < vs. >10 mm tumors
- management of R1 excision
- surgery
- follow-up
@AmanChauhanMD @OncoThor @FlavioRochaMD
https://t.co/UDLJ8ZI75f

[Jonathan Loree @jonathanloree]

Congrats @RobertoFedrigo on your new manuscript on treatment attrition in NETs! Shows how many patients never reach later lines of therapy. Important context as we interpret NETTER-2 and debate earlier PRRT use.
https://t.co/LYDvp8lli1

#NETs #PRRT #NETTER2 #oncology

[Jonathan Loree @jonathanloree]

@aparna1024 Prognostic vs predictive important as well. Stellar looked pretty similar for HR and one of our biggest randomized data sets.

[Jonathan Loree @jonathanloree]

@fireflyann @BCCancer @bccancerfdn @coloncanada Thanks for sharing both here and in the other groups!

[Jonathan Loree @jonathanloree]

How would you prefer to be screened for colorectal cancer? 🩺
We’re surveying people to better understand preferences — including whether blood-based tests could reduce barriers. Please retweet &
Share your voice: https://t.co/KYlF6TgWFq

@BCCancer @bccancerfdn @coloncanada

[CCTG @CDNCancerTrials]

Applications are being accepted for the #CCTG 2026-2027 New Investigator Cancer Trials Practicum - a training program that enables the brightest new Canadian oncology researchers to acquire training & experience in clinical trial conduct. How to apply: https://t.co/XKoxykJcCr

[Cancers MDPI @Cancers_MDPI]

AI meets digital pathology! 🔬 We used machine learning on whole-slide images of neuroendocrine tumors to classify grade, differentiation & prognosis.

✍ Authors: Amir Hadjifaradji et al. @jonathanloree @BCCancer @bccancerfdn

🌻 Read in @Cancers_MDPI
https://t.co/u5MhkS7gYD

[Jonathan Loree @jonathanloree]

A nice retrospective study looking at chemo doublets in biliary tract cancer. "FOLFOX Versus FOLFIRI as Second‐Line Chemotherapy in Patients With Advanced Biliary Tract Cancers: A Multicenter, Italian Study - Pircher - 2026" https://t.co/FPzT3MMXJO

[Jonathan Loree @jonathanloree]

@ronanhsieh @smitha42 Looking forward to working with you!

[Eric Topol @EricTopol]

The "Big Bang" of cancer evolution: for colon cancer, evidence that immune evasion occurs very early
https://t.co/dC9vo81f7e

[A.n.n. @fireflyann]

So Dill started this to help Canadian patients...
and once he got the platform running for Canada...
he made it global. In a weekend.

Oh, Canada!
@ccranorg @coloncanada
@CAMO_ACOM @CDNCancerTrials @uoftmedicine @Sunnybrook @BCCancer
@GillSharlene @jonathanloree @ocall0

[Jonathan Loree @jonathanloree]

@RonaYaeger Similar in CO.26 https://t.co/2oLHQkDVJX, however didn’t see responses: https://t.co/xW238F26aM

[Jonathan Loree @jonathanloree]

Results from DYNAMIC-III RCT of ctDNA-guided adjuvant tx in stage III colon cancer in Nature Med.
🙏 to pts, providers & @JeanneTie
🇨🇦🇦🇺 @CDNCancerTrials & @GICancer Collab

#ESMO2025 Presidential | Supported by @CIHR_IRSC & @cancersociety in 🇨🇦
🔗 https://t.co/8DcYxgy2P3

[Sharlene Gill, MD, MPH, MBA, FASCO @GillSharlene]

Excited to be at the #ESMO25 launch of the phase 3 @CDNCancerTrials 🇨🇦 #BATTMAN CO.33
BOT/BAL vs BSC in refractory MSS mCRC #unmetneed #trialsthatmatter
Congrats to @jonathanloree 🙌
@ocall0 @Agenus_Bio
@GICancer @JeanneTie
Let’s get this done! 🇨🇦 🇦🇺 🇫🇷
@coloncanada @ccranorg
@OncoAlert